(Total Views: 396)
Posted On: 08/19/2020 11:55:21 AM
Post# of 26
$XRTXF XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries.
eResearch initiated coverage with a "Speculative Buy" rating and one-year price target of $2.30. https://api.quotemedia.com/supplement/news-st...8654212797
eResearch initiated coverage with a "Speculative Buy" rating and one-year price target of $2.30. https://api.quotemedia.com/supplement/news-st...8654212797
(0)
(0)
